Monoclonal site-directed conjugation

The conjugation of deacetylvinblastine to a monoclonal antibody that recognizes a tumor-associated antigen results in an agent with substantial antitumor activity in mice with relatively little toxicity (la). Conjugates of this type are of obvious interest for future clinical trials as site-directed cancer chemotherapeutic agents. 

Alternatively, GFP can be visualized using rabbit polyclonal antibody raised against GFP purified directly from A. victoria. This anti-GFP antibody facilitates the detection of native GFP, recombinant GFP, and GFP-fusion proteins both by immunofluorescence and brightfield microscopy, as well as by western blot analysis and immunoprecipitation. Direct anti-GFP conjugates made from a complete serum or from an IgG fraction are available from Invitrogen (http //www.invitrogen.com/ site/us/en/home.html). Additional options for your research offered by Invitrogen include two mouse monoclonal antibodies and a chicken IgY fraction. 

Several clinical trials have evaluated (or continue to evaluate) monoclonal antibodies to which a radioactive tag has been conjugated. These are usually employed as potential anti-cancer agents. The rationale is selective delivery of the radioactivity directly to the tumour site. Most of the radioisotopes being evaluated are /i-emitters these include I and I (iodine), Re and Re (rhenium) and (yttrium). The medium-energy radioactivity these emit is capable of penetrating... 

---